
UK standards for microbiology investigations

User manual template



Acknowledgments

UK Standards for Microbiology Investigations (SMIs) are developed under the auspices of Public Health England (PHE) working in partnership with the National Health Service (NHS), Public Health Wales and with the professional organisations whose logos are displayed below and listed on the website <https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical-laboratories>. SMIs are developed, reviewed and revised by various working groups which are overseen by a steering committee (see <https://www.gov.uk/government/groups/standards-for-microbiology-investigations-steering-committee>).

The contributions of many individuals in clinical, specialist and reference laboratories who have provided information and comments during the development of this document are acknowledged. We are grateful to the medical editors for editing the medical content.

For further information please contact us at:

Standards Unit

Microbiology Services

Public Health England

61 Colindale Avenue

London NW9 5EQ

E-mail: [standards@phe.gov.uk](mailto:standards@phe.gov.uk)

Website: <https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical-laboratories>

PHE Publication gateway number: 2015368

UK Standards for Microbiology Investigations are produced in association with:



Contents

Acknowledgments 2

Contents 2

Amendment table 4

UK Standards for Microbiology Investigations: scope and purpose 5

Scope 8

Key contact details 8

Laboratory location and access details 8

Collection and transport of specimens 8


Types of services offered and how to use the laboratory 9

Quality Assurance and governance 9

Test Turnaround times and parameters of performance 10

Reporting Results 10

References 11



Amendment table

Each SMI method has an individual record of amendments. The current amendments are listed on this page. The amendment history is available from [standards@phe.gov.uk](mailto:standards@phe.gov.uk).

New or revised documents should be controlled within the laboratory in accordance with the local quality management system.

|  |  |
| --- | --- |
| Amendment no/date. | New amendment number/dd.mm.yy <tab+enter> |
| Issue no. discarded. | #.# <tab+enter> |
| Insert Issue no. | #.# <tab+enter> |
| **Section(s) involved** | **Amendment** |
|  |  |

|  |  |
| --- | --- |
| Amendment no/date. | # <tab+enter>/dd.mm.yy <tab+enter> |
| Issue no. discarded. | #.# <tab+enter> |
| Insert Issue no. | #.# <tab+enter> |
| **Section(s) involved** | **Amendment** |
| Xxxxxx | Xxxxxx |
| Xxxxxxx | Xxxxxx |
| Xxxxxxx | xxxxxx |
|  |  |
|  |  |

UK Standards for Microbiology Investigations[[1]](#footnote-1)#: scope and purpose

Users of SMIs

SMIs are primarily intended as a general resource for practising professionals operating in the field of laboratory medicine and infection specialties in the UK.

SMIs provide clinicians with information about the available test repertoire and the standard of laboratory services they should expect for the investigation of infection in their patients, as well as providing information that aids the electronic ordering of appropriate tests.

SMIs provide commissioners of healthcare services with the appropriateness and standard of microbiology investigations they should be seeking as part of the clinical and public health care package for their population.

Background to SMIs

SMIs comprise a collection of recommended algorithms and procedures covering all stages of the investigative process in microbiology from the pre-analytical (clinical syndrome) stage to the analytical (laboratory testing) and post analytical (result interpretation and reporting) stages.

Syndromic algorithms are supported by more detailed documents containing advice on the investigation of specific diseases and infections. Guidance notes cover the clinical background, differential diagnosis, and appropriate investigation of particular clinical conditions. Quality guidance notes describe laboratory processes which underpin quality, for example assay validation.

Standardisation of the diagnostic process through the application of SMIs helps to assure the equivalence of investigation strategies in different laboratories across the UK and is essential for public health surveillance, research and development activities.

Equal partnership working

SMIs are developed in equal partnership with PHE, NHS, Royal College of Pathologists and professional societies.

The list of participating societies may be found at <https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical-laboratories>. Inclusion of a logo in an SMI indicates participation of the society in equal partnership and support for the objectives and process of preparing SMIs. Nominees of professional societies are members of the steering committee and working groups which develop SMIs. The views of nominees cannot be rigorously representative of the members of their nominating organisations nor the corporate views of their organisations. Nominees act as a conduit for two way reporting and dialogue. Representative views are sought through the consultation process.

SMIs are developed, reviewed and updated through a wide consultation process.

Quality assurance

NICE has accredited the process used by the SMI working groups to produce SMIs. The accreditation is applicable to all guidance produced since October 2009. The process for the development of SMIs is certified to ISO 9001:2008.

SMIs represent a good standard of practice to which all clinical and public health microbiology laboratories in the UK are expected to work. SMIs are NICE accredited and represent neither minimum standards of practice nor the highest level of complex laboratory investigation possible. In using SMIs, laboratories should take account of local requirements and undertake additional investigations where appropriate. SMIs help laboratories to meet accreditation requirements by promoting high quality practices which are auditable. SMIs also provide a reference point for method development.

The performance of SMIs depends on competent staff and appropriate quality reagents and equipment. Laboratories should ensure that all commercial and in-house tests have been validated and shown to be fit for purpose. Laboratories should participate in external quality assessment schemes and undertake relevant internal quality control procedures.

Patient and public involvement

The SMI working groups are committed to patient and public involvement in the development of SMIs. By involving the public, health professionals, scientists and voluntary organisations the resulting SMI will be robust and meet the needs of the user. An opportunity is given to members of the public to contribute to consultations through our open access website.

Information governance and equality

PHE is a Caldicott compliant organisation. It seeks to take every possible precaution to prevent unauthorised disclosure of patient details and to ensure that patient-related records are kept under secure conditions.

The development of SMIs is subject to PHE equality objectives <https://www.gov.uk/government/organisations/public-health-england/about/equality-and-diversity>. The SMI working groups are committed to achieving the equality objectives by effective consultation with members of the public, partners, stakeholders and specialist interest groups.

Legal statement

While every care has been taken in the preparation of SMIs, PHE and any supporting organisation, shall, to the greatest extent possible under any applicable law, exclude liability for all losses, costs, claims, damages or expenses arising out of or connected with the use of an SMI or any information contained therein. If alterations are made to an SMI, it must be made clear where and by whom such changes have been made.

The evidence base and microbial taxonomy for the SMI is as complete as possible at the time of issue. Any omissions and new material will be considered at the next review. These standards can only be superseded by revisions of the standard, legislative action, or by NICE accredited guidance.

SMIs are Crown copyright which should be acknowledged where appropriate.

Suggested citation for this document

Public Health England. (YYYY <tab+enter>). Title of SMI goes here <tab+enter>. UK Standards for Microbiology Investigations. X # <tab+enter> Issue #.# <tab+enter>. <https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical-laboratories>

Scope

*Include the accreditation status of the laboratory.*

*Explain on who the intended user of the document is and what it does and does not cover (eg does not cover treatment or infection control). If further relevant documents exist, consider listing them here.*

*Be clear whether this is for patient use or not.*

*How to use this document will depend on its structure - hyperlinks etc.*

Key contact details

*This section should include:*

* *instructions on making enquiries for results and requests for additional tests on existing samples*
* *advice on how patients should obtain results; clearly explain whether patients should or should not call the laboratory directly for results − this is a significant issue regarding data security and clinical risk*
* *contact details for key members of staff*

Laboratory location and access details

*This section should include:*

* *whether the public has access to the laboratory or not and where phlebotomy services are located and times available*
* *location maps for both outside and inside the hospital if not contained in other documents*
* *the names and addresses of laboratories to which work is routinely referred*
* *working hours*

Collection and transport of specimens

*This section should include:*

* *procedures for the proper collection and handling of primary samples, including appropriate health and safety*
* *an explanation of any clinical procedure to be performed, to enable informed consent. Any specific requirements for patient consent (eg consent to disclose clinical information and family history to relevant healthcare professionals, where referral is needed)*
* *patient information sheets*
* *instructions for preparation of the patient (eg instructions to caregivers, phlebotomists, sample collectors and patients)*
* *instructions on how to determine the identity of the patient from whom a primary sample is collected*
* *verification that the patient meets pre-examination requirements eg fasting status, medication status (time of last dose or cessation), sample collection at a predetermined time (or time intervals)*
* *instructions for sample collectors, including instructions for patient-collected samples eg type and amount of the primary sample(s) to be collected with descriptions of the primary sample containers (pictures may be helpful) and any necessary additives; special timing of collection, where needed; clinical information relevant to or affecting sample collection, examination performance or result interpretation (eg history of administration of drugs); information on how to order supplies of the relevant containers, forms, labels etc. This may be displayed in table format*
* *the identity of the person collecting the primary sample and the collection date, and, when needed, the collection time for the safe disposal of materials used in the collection*
* *instructions for labelling of primary samples in a manner that provides an unequivocal link with the patients from whom they are collected for example; high risk samples (including radioactive isotopes)*
* *instructions for transportation of samples, including any special handling needs and instructions for proper storage conditions before collected samples are delivered to the laboratory and in a manner that ensures the integrity of the sample and safety for the carrier, general public and receiving laboratory, in compliance with established requirements*
* *laboratory’s criteria for accepting and rejecting samples*

Types of services offered and how to use the laboratory:

* *details of any out-of-hours service or shift system at the laboratory. Outline which services will always be provided and which will only be provided in consultation*
* *statement on the provision of services to the public. Distinguish between infection control services and infectious diseases services. Identify specialist areas eg regional or national reference functions.*
* *information on consent and testing services for high risk samples such as Ebola, MERS-CoV and novel Influenza viruses. Include diagnostic, clinical advice, infection control, outbreaks, antibiotic stewardship, etc*
* *instructions for completion of the request form (pictures may be helpful) or electronic request*
* *availability of clinical advice on ordering of examinations and interpretation of examination results*
* *examinations offered by the laboratory. Include as appropriate information concerning samples provided in general categories or for groups of related investigations (separate in-house and referred tests as separate tables) required, primary sample volumes, specific swab types eg for Chlamydia testing, special precautions, turnaround times (which may also be provided in general categories or for groups of examinations); procedures for medico-legal samples; compliance with the Human Tissue Act. Include relevant clinical algorithms with links to policies of local or national NHS organisations that are relevant eg HIV testing, MRSA screening, dyspepsia investigation and management, Clostridium difficile testing, immunisation against infectious diseases (‘Green Book’)*
* *confirmatory tests not directly requested may be performed by the laboratory if such tests aid interpretation of the initial test result (also known as reflex testing) – eg a failed HBV vaccine response allowably triggers a test for surface antigen of hepatitis B virus (HBsAg)*
* *provision and arrangement for accessing of immunoglobulins and vaccines (eg VZIG, HNIG, rabies prophylaxis*)

Quality assurance and governance

*This section should include the quality assurance and governance at the laboratory; the complaints procedure; the laboratory’s policy on protection of personal information; and the fax and email policy.*

*Also include a statement on the accreditation status, link to the accreditation body, and list of which (if any) tests are excluded from the accredited scope of practice (Accreditation status of test repertoire).*

Test turnaround times and parameters of performance

*This section will include relevant information on:*

* *biological reference intervals or clinical decision values (document their basis)*
* *a list of factors known to significantly affect the performance of the examination or the interpretation of the results (uncertainty)*
* *performance characteristics – sensitivity/specificity − of the tests*
* *pitfalls of serology, PCR, culture etc. As well as having such things embedded within individual tests, consider including passively acquired antibody, cross reactivates for IgM assays and sample quality (eg swabs and PCR results)*
* *a table to state the length of storage for samples that may need re-testing*
* *time limits for requesting additional examinations*
* *costs of tests*
* *validation/verification data*

Reporting results

*In the reporting section, provide instructions for making results enquiries, including the minimum time required before phoning for a test result unless the sample has been marked as urgent. It is always advisable to check the LIMs system before phoning for results.*

*Also include information relating to report categories (interim, final, amended) and information relating to Notification of Infectious Diseases.*

References

1. # Microbiology is used as a generic term to include the two GMC-recognised specialties of Medical Microbiology (which includes Bacteriology, Mycology and Parasitology) and Medical Virology. [↑](#footnote-ref-1)